Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Regeneron Pharmaceuticals, Inc (0R2M) fair value: what the stock is really worth
As of Oct 2, 2026: fair value of Regeneron Pharmaceuticals, Inc $1,039, price $737, upside +40.9%, quality 72 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? Yes
- Good quality? Yes
- Add to watchlist
RP
Broad data
Sep 24, 2026
Regeneron Pharmaceuticals, Inc
0R2M · LSEUndervaluedThe stock appears undervalued with acceptable quality.
✓Fair value $1,039 · Undervalued (+40.9%)
✓Quality 72/100
✓Healthy Growth (revenue 5y +11.0 %/yr)
✓Highly profitable · 27.9% net margin (TTM)
✓generates free cash flow
✓0.5% dividend yield · Well covered
✓Wide moat 78/100
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range $480.17 – $1,197 · fair‑value band $553.24 – $1,759 · the $737.06 price screens below the $1,039 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions.
Show more
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines to treat various diseases worldwide. The company develops product candidates to treat eye, allergic and inflammatory, cardiovascular, metabolic, neurological, infectious, and rare diseases; and cancer, hematologic conditions. It also offers EYLEA injections for wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; retinopathy of prematurity; Dupixent injection to treat atopic dermatitis and asthma; Libtayo injection for metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection to treat heterozygous familial hypercholesterolemia (HoFH); and Kevzara solution for rheumatoid arthritis. It has license and collaboration agreement with Bayer for the development and commercialization of EYLEA 8 mg and EYLEA; Alnylam Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for diseases by addressing therapeutic disease targets expressed in the eye and central nervous system; Intellia Therapeutics, Inc. to advance CRISPR/Cas9 gene-editing technology for in vivo therapeutic development for therapies focused on neurological and muscular diseases; Hansoh Pharmaceuticals Group Company Limited to acquire development and commercial rights for HS-20094, a dual GLP-1/GIP receptor; and Tessera Therapeutics, Inc. develops and commercializes TSRA-196, an investigational gene editing therapy for Alpha-1 antitrypsin deficiency. Additionally, the company has a strategic collaboration with Telix Pharmaceuticals Limited to develop and commercialize radiopharmaceutical therapies. It also has a strategic collaboration with CytomX Therapeutics, Inc. to create conditionally-activated bispecific cancer therapies. The company was incorporated in 1988 and is based in Tarrytown, New York.
Stock analysis
Regeneron Pharmaceuticals, Inc (0R2M) currently trades at $737.06, while our model-based Fair Value estimate is $1,039, implying the stock looks roughly 29.0% undervalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $1,353 per share, and 13 of the 26 models we run sit above the $737.06 price.
Bear case: the Asset-Based group reads lowest at $193.85, and 13 of the 26 models stay below the price. Evidence for this calculation is high.
Scenario range: $553.24 (bear) to $1,759 (bull), the price of $737.06 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 72/100 (solid quality).
Healthy Growth: Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Regeneron Pharmaceuticals, Inc reported revenue of $14.3B in FY2025 versus $16.1B in FY2021, a compound −2.8%/yr. Reported net income was $4.5B in FY2025, compounding −13.6%/yr from FY2021.
Key figures
Market cap $80.0B · P/E ratio 0.1 · P/S ratio 0.03 · EPS (TTM) $70.31 · Dividend yield 0.5% · Net margin 31.4% · Return on equity 14.0% · Return on assets (EBIT) 17.4%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 58 out of 100 (medium confidence).
What moves the price
The share trades about 13% below its 52-week high and 33% above its 52-week low, currently above its 200-day average.
Fair Value models
Bear $553.24
Fair Value $1,039
Bull $1,759
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($50.41 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
FCF DCF
$634.85
$961.84
$1,981
74
Residual Income
$280.41
$366.68
$589.96
74
Growth DCF
$597.95
$1,052
$1,940
72
All 26 models by family
DCF Models
FCF DCF
$634.85
$961.84
$1,981
74
Owner Earnings
$604.18
$1,304
$2,719
68
5Y Revenue Exit
$385.93
$604.42
$1,058
68
5Y EBITDA Exit
$484.43
$803.56
$1,428
70
5Y P/E Exit
$663.97
$1,452
$2,526
65
10Y Revenue Exit
$456.28
$867.19
$1,098
64
10Y EBITDA Exit
$536.64
$1,074
$1,985
62
10Y P/E Exit
$664.72
$1,452
$2,748
58
Earnings-Based
Graham-Dodd
$283.56
$1,977
$2,775
63
Lynch FV
$759.22
$1,085
$1,410
61
PEG = 1.0
$759.22
$1,085
$1,410
57
EPV
$278.59
$318.01
$352.02
70
Dividend Discount
Gordon GGM
$30.10
$59.98
$90.83
67
DDM Multi-Stage
$30.10
$51.84
$63.32
67
Multiples
P/E Multiple
$625.49
$833.99
$1,042
63
P/S Multiple
$248.93
$331.91
$414.89
58
P/B Multiple
$531.67
$708.89
$886.11
55
EV/EBIT
$490.37
$644.19
$798.01
63
EV/EBITDA
$411.26
$538.71
$666.16
64
EV/Revenue
$261.25
$360.82
$460.40
51
Asset-Based
NCAV (Graham)
$144.66
$193.85
$289.33
51
Growth DCF
Growth DCF
$597.95
$1,052
$1,940
72
Rev-Margin DCF
$389.97
$687.87
$1,251
67
Economic Profit
Residual Income
$280.41
$366.68
$589.96
74
ROIC Compounder
$278.59
$358.88
$447.94
70
Growth Earnings
Growth-Adj P/E
$947.18
$1,353
$1,759
67
Notify me when 0R2M reaches fair value
Put 0R2M on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
72/100
Of which business quality 70 · Market factors (momentum, volatility) 67
Profitability
60
Margins and returns on capital today
Quality Growth
38
Are margins and returns improving?
Cashflow
80
Earnings quality: real cash, not paper profit
Fin. Strength
81
Balance sheet, leverage, solvency risk
Investment
54
Disciplined investing over empire-building
Low Volatility
82
Calm price path (market factor)
Momentum
59
Price trend over the last 3–12 months (market factor)
52W Momentum
62
Distance to the 52-week high (market factor)
Net Issuance
99
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
93/100
Revenue growth appears healthy and is supported by profitability and cash-flow quality.
Revenue growth 1 year
+1.0%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.6%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.0%
Start year 2020 (pandemic). Over 10 years: +13.3% a year
Revenue growth 35 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+25.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+6.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+6.3%
Dividend (yield on the price)0.5%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.6.3% vs 22.3%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.42% → 26%
Start year 2020 (pandemic)
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far and less than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+5.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+9.2%
Yearly sales growth analysts expect, extended to five years.
After inflation (USA: IMF forecast 2.4% a year to 2030, 3.1% from 2016 to 2025) that is about +2.8% a year for the price and +6.7% for the forecasts.
Forecast 2026 (sales)+17.8%
Forecast 2027 (sales)+8.3%
Projected 2028 (sales)+7.6%
Projected 2029 (sales)+6.8%
Projected 2030 (sales)+6.0%
Watch 0R2M, get fair value alerts →
Compare Regeneron Pharmaceuticals, Inc with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Context: sector, industry, market
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: UK Stocks
- Valuation of the UK market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Explore undervalued stocks
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Regeneron Pharmaceuticals, Inc (0R2M) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of $1,039 versus a price of $737.06, about +41% upside (undervalued).
What is the fair value of 0R2M?
Our model-based fair value for Regeneron Pharmaceuticals, Inc is $1,039 (as of Sep 24, 2026), built from audited fundamentals. The current price: $737.06.
What is the quality score of 0R2M?
Regeneron Pharmaceuticals, Inc has a Quality Score of 72/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Regeneron Pharmaceuticals, Inc (0R2M)?
Our model-based price target is the fair value of $1,039 (as of Sep 24, 2026) from 26 valuation models. Cautious scenario $553.24, optimistic scenario $1,759. It is a calculation from audited fundamentals, not an analyst target.
What is the Regeneron Pharmaceuticals, Inc stock forecast for 2026?
Our models put fair value at $1,039, about +41% upside versus a price of $737.06 (undervalued). Cautious scenario $553.24, optimistic scenario $1,759. The calculation is refreshed regularly with new filings.
What is the revenue of Regeneron Pharmaceuticals, Inc (0R2M)?
Regeneron Pharmaceuticals, Inc reported trailing-twelve-month revenue of about $15.5B (latest available figure, as of Sep 24, 2026).
Does Regeneron Pharmaceuticals, Inc pay a dividend?
Regeneron Pharmaceuticals, Inc currently shows a dividend yield of about 0.49% relative to its recent price (as of Sep 24, 2026).
What growth is priced into Regeneron Pharmaceuticals, Inc (0R2M)?
For today's price to be fair in a discounted-cash-flow model, Regeneron Pharmaceuticals, Inc would have to grow free cash flow by +5.3 % per year for five years (discount rate 9.0 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +11.0 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 0R2M use?
Our models discount Regeneron Pharmaceuticals, Inc at 9.0 %: a base by market capitalisation (unknown), damped by beta 0.19, country premium for United Kingdom. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Regeneron Pharmaceuticals, Inc that is +5.3 % per year a year over ten years, using the same discount rate (9.0 %) and the same formula as our fair value.
How much growth has Regeneron Pharmaceuticals, Inc (0R2M) delivered so far?
Over the past 5 years revenue at Regeneron Pharmaceuticals, Inc grew +11.0 % a year. The price currently implies +5.3 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
What is the free cash flow yield of Regeneron Pharmaceuticals, Inc (0R2M)?
The free-cash-flow yield on the price is 5.10 %: that much free cash flow Regeneron Pharmaceuticals, Inc produces per unit of market value. When it exceeds the discount rate of our models (9.0 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Regeneron Pharmaceuticals, Inc (0R2M)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Regeneron Pharmaceuticals, Inc it is $1,039 per share (as of Sep 24, 2026), against a price of $737.06. It is the blended result of 26 valuation models (cash flow, earnings, asset, dividend).
Is Regeneron Pharmaceuticals, Inc stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 0R2M trades below its calculated fair value: price $737.06, fair value $1,039, a gap of about +41% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 0R2M?
No. The price is what the market pays today ($737.06); the fair value is what the company's own numbers justify ($1,039). For Regeneron Pharmaceuticals, Inc the two are $301.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Regeneron Pharmaceuticals, Inc worth?
The market values Regeneron Pharmaceuticals, Inc at about $80.0B (market capitalisation, as of Sep 24, 2026). Per share that is $737.06; our models calculate a fair value of $1,039 per share.
What do the bullish and bearish scenarios say about 0R2M?
Our models span a range for Regeneron Pharmaceuticals, Inc: cautious scenario $553.24, base $1,039, optimistic $1,759 per share (as of Sep 24, 2026, price $737.06). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 0R2M from its 52-week high?
Regeneron Pharmaceuticals, Inc trades at $737.06, about 13% below its 52-week high of $851.21 and 33% above the low of $552.67 (as of Oct 2, 2026). Distance from the high says nothing about value: that is what the fair value of $1,039 is for.
Is Regeneron Pharmaceuticals, Inc stock attractive at the current price?
The data as of Sep 24, 2026: price $737.06, calculated fair value $1,039 (+41%), Quality Score 72/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 0R2M calculated?
We run Regeneron Pharmaceuticals, Inc through 26 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $1,039, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Regeneron Pharmaceuticals, Inc currently trades 29 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Regeneron Pharmaceuticals, Inc (0R2M)?
The closing price on Oct 2, 2026 was $737.06. Our model-based fair value is $1,039, about +41% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Regeneron Pharmaceuticals, Inc right now?
The rarer combination: high quality (72/100) AND below fair value. That earns a closer look rather than a quick verdict. The model range is unusually wide ($553.24 to $1,759). The outcome hinges heavily on assumptions, so read the point estimate with caution.
Where does the earnings growth of Regeneron Pharmaceuticals, Inc (0R2M) come from?
Earnings per share at Regeneron Pharmaceuticals, Inc grew +24.2 % a year from 2014 to 2025. Broken into its drivers: revenue per share +15.3 %, EBIT margin +0.2 %, tax rate +5.4 %, residual (interest, one-offs) +2.0 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Regeneron Pharmaceuticals, Inc
How large is the market capitalisation of Regeneron Pharmaceuticals, Inc (0R2M)?
The market capitalisation of Regeneron Pharmaceuticals, Inc is $80.0B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/E ratio of Regeneron Pharmaceuticals, Inc (0R2M)?
The price-to-earnings ratio of Regeneron Pharmaceuticals, Inc is 0.1 (as of Aug 5, 2026). Price to earnings: how many years of current profit you pay for the stock. A P/E of 10 means ten years of profit.
What is the P/S ratio of Regeneron Pharmaceuticals, Inc (0R2M)?
The price-to-sales ratio of Regeneron Pharmaceuticals, Inc is 0.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Regeneron Pharmaceuticals, Inc (0R2M)?
Earnings per share at Regeneron Pharmaceuticals, Inc are $70.31 (price ÷ EPS = P/E 0.1). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Regeneron Pharmaceuticals, Inc (0R2M)?
The dividend yield of Regeneron Pharmaceuticals, Inc is 0.5% (payout 5.2%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Regeneron Pharmaceuticals, Inc (0R2M)?
The net margin of Regeneron Pharmaceuticals, Inc is 31.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Regeneron Pharmaceuticals, Inc (0R2M)?
The return on equity (ROE) of Regeneron Pharmaceuticals, Inc is 14.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Regeneron Pharmaceuticals, Inc (0R2M)?
On an EBIT basis the return on assets of Regeneron Pharmaceuticals, Inc is 17.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Regeneron Pharmaceuticals, Inc (0R2M)?
The operating margin of Regeneron Pharmaceuticals, Inc is 33.1% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Regeneron Pharmaceuticals, Inc (0R2M)?
Revenue at Regeneron Pharmaceuticals, Inc is growing +16.7% versus a year earlier (3y avg +5.6%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Regeneron Pharmaceuticals, Inc (0R2M)?
Earnings per share at Regeneron Pharmaceuticals, Inc are growing −4.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net cash does Regeneron Pharmaceuticals, Inc (0R2M) hold?
Regeneron Pharmaceuticals, Inc holds more cash than debt, $418M net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed
Continue in the live analysis
Fair value and trend for 35,000+ stocks, watchlist, comparison and the diversification check. You can also try 14 days of Pro there, no card.
Open the live analysis →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.